

Assessing incomplete sampling of disease transmission networks


Meeting with Paul

Derek Sonderegger, PhD - Northern Arizona University

April 9, 2019

Colaborators

- ▶ Work that I have done with the Pathogen and Microbiome Institute at NAU and we are just a couple months into the project.



- ▶ Dr Paul Keim
- ▶ Dr Jason Sahl

Background Information

Two worrisome Healthcare Acquired Infections (HAIs)

- ▶ MRSA
 - ▶ Methicillin-resistant *Staphylococcus aureus*
 - ▶ Resistant to many common antibiotics
- ▶ *C. Diff*
 - ▶ *Clostridioides difficile*
 - ▶ Our disease of interest

Clostridioides difficile

- ▶ A spore-forming bacteria
 - ▶ Spores can survive for months in the environment
 - ▶ Bacteria die when exposed to oxygen.
 - ▶ Very difficult to work with in the lab.
- ▶ *C. diff* is widely distributed
 - ▶ Spores are widely found in the environment
 - ▶ People and animals can be asymptomatic carriers
- ▶ Resistant to many commonly used antibiotics

Human Infection

- ▶ Causes diarrhea, fever, nausea, and abdominal pain
- ▶ Spread through fecal contamination
- ▶ Additional \$4.8 billion each year in health care costs
 - ▶ 290,000 Americans sickened by the bacteria in a hospital or other health care facility each year.
 - ▶ 27,000 people in the U.S. die while infected with *C. diff* annually.

Common infection cycle

- ▶ In a healthy gut biome, *C. diff* can't strongly establish due to bacterial competition.
- ▶ In patients under a common antibiotic treatment, *C. diff* can flourish.
- ▶ Prescribed antibiotics for some other reason (e.g. pneumonia)
 - ▶ *C. diff* might already be present in the patient.
 - ▶ Come into contact with *C. diff* via live bacteria or spores from another patient.

Medicare Implications

- ▶ Won't reimburse costs for treating infections acquired at a healthcare facility
- ▶ If the rate of Healthcare Acquired Infections (HAIs) is too high, Medicare will deduct one percent from their OVERALL reimbursements to the facility.
- ▶ Medicare defines any diagnosis of *C. diff* that occurs 3 days after admission as “healthcare acquired”.

Goal: Estimate HAI rate


- ▶ Individual patients have the genome of their strain of *C. diff* sequenced.
- ▶ Group strains into clusters if they differ by at most 2 SNPs.
 - ▶ Use Single-Linkage clustering method: represents evolution along a chain of infections
 - ▶ Within patient variability suggests that maybe this needs to be evaluated.

Data!


Oxfordshire Data

- ▶ Eyre *et al* 2013 describes a study which genotyped nearly all cases of *C. diff* in over three years in Oxfordshire, UK.
- ▶ Of the 1250 cases that were evaluated, $N = 1223$ were successfully genotyped.

Oxfordshire Time/Clusters



Oxfordshire Cluster Size Distribution



Defining HAI rate from full data

- ▶ For each cluster, the first time a strain is observed it is considered environmentally acquired.
- ▶ The second (or third, or fourth, ..) time a strain is observed, it is healthcare acquired.

$$HAI = \frac{N - ||\mathcal{I}||}{N} = 1 - \frac{||\mathcal{I}||}{N}$$

N = Number of Patients

\mathcal{I} = Set of strain identifiers

$||\mathcal{I}||$ = Actual Number of Clusters/Strains

- ▶ Knowing $||\mathcal{I}||$ is the key to calculating HAI rate!

Observed Number of Clusters/Strains under Simple Random Sampling

$$\widehat{HAI}_{naive} = 1 - \frac{||I||}{n}$$

n = sample size

I = Set of observed strains

$||I||$ = Observed Number of Clusters/Strains